ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 901-925 of 1,000 matching filings.

Per page
25
Current page
37
4 File 001-35112

4

Filing date
07 Feb 2020
Reporting date
19 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
3 File 001-35112

3

Filing date
07 Feb 2020
Reporting date
19 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D

SC 13D

Filing date
07 Feb 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-236014

EFFECT filing

Filing date
06 Feb 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-55247

SC 13G/A filing

Filing date
05 Feb 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Feb 2020
Reporting date
03 Feb 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
30 Jan 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-55247

SEC SCHEDULE 13G

Filing date
27 Jan 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP

Filing date
27 Jan 2020
Reporting date
27 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN

Filing date
27 Jan 2020
Reporting date
27 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE

Filing date
27 Jan 2020
Reporting date
27 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES

Filing date
27 Jan 2020
Reporting date
27 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
F-6 File 333-236014

FORM F-6

Filing date
22 Jan 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED

Filing date
21 Jan 2020
Reporting date
20 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN

Filing date
21 Jan 2020
Reporting date
20 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA

Filing date
13 Jan 2020
Reporting date
13 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA

Filing date
13 Jan 2020
Reporting date
13 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA

Filing date
06 Jan 2020
Reporting date
06 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED

Filing date
06 Jan 2020
Reporting date
06 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Jan 2020
Reporting date
02 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-

Filing date
30 Dec 2019
Reporting date
30 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP

Filing date
23 Dec 2019
Reporting date
23 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB

Filing date
23 Dec 2019
Reporting date
23 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO

Filing date
20 Dec 2019
Reporting date
20 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER

Filing date
17 Dec 2019
Reporting date
17 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .